Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Western blot analysis of ERK phosphorylation in HUVECs stimulated for 10 min with AGR2 coupled with or without FGF/VEGF. The concentration of AGR2 is 500 ng/ml. The concentration of VEGF is 5 ng/ml. PD173074: FGFR inhibitor; Axitinib: VEGFR inhibitor (2 nm); BEV: VEGF antibody bevacizumab (5 μg/ml). Quantification of ERK activity was performed by normalizing phosphorylated ERK to β-actin, untreated control (lane 1) was set to 1. All data represent four independent biological replicates and shown as means±s.d. Asterisks indicate significant differences (*, Pless than or equal to0.05; **, Pless than or equal to0.01).

    Oncogene, 2017, 36(36):5098-5109. Axitinib purchased from Selleck.

    Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

  • Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M{LOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH5TWM2OD1yLkCwNFA2OTNizszN M3PDZnNCVkeHUh?=
NCI-H1703 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjYTWM2OD1yLkCwNFkxOiEQvF2= Mm\DV2FPT0WU
KASUMI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DRdWlEPTB;MD6wNFY5OiEQvF2= M4m4PXNCVkeHUh?=
CGTH-W-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfmdmxKSzVyPUCuNFA4OjJizszN M2T5XnNCVkeHUh?=
A204 NW\6UmV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEC5PVIh|ryP NWDkfWg5W0GQR1XS
HOP-62 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMUC4N|Yh|ryP M3fwSHNCVkeHUh?=
H-EMC-SS Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDYTWM2OD1yLkGxNFA2KM7:TR?= Ml;0V2FPT0WU
KU812 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnz[npKSzVyPUCuNVY2PzdizszN M3PK[3NCVkeHUh?=
EM-2 M{XZXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIn4d3VKSzVyPUCuNVY5OTZizszN MoDDV2FPT0WU
LAMA-84 NWLuS4EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn5TWM2OD1yLkG3OlY2KM7:TR?= NXnkPGZqW0GQR1XS
JAR NVL1dXhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkO5PFkh|ryP NHX0NpFUSU6JRWK=
G-361 NXPMd5g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm0d2hKSzVyPUCuN|I{OjVizszN NGDzeYRUSU6JRWK=
KG-1 M1\pcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1SWxKSzVyPUCuN|c3PDJizszN MVXTRW5ITVJ?
BV-173 M2Twb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33pUmlEPTB;MD6zPVMzKM7:TR?= Ml\3V2FPT0WU
K5 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjzSWhKSzVyPUCuOFIyOjdizszN MV\TRW5ITVJ?
MEG-01 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XIUWlEPTB;MD60NlM3OSEQvF2= NGLRPYpUSU6JRWK=
MFM-223 NUDFPHVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoiwTWM2OD1yLkS0O|c3KM7:TR?= MoG5V2FPT0WU
BE-13 NV7zVFhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnThTWM2OD1yLkWxNFA5KM7:TR?= NID2Z25USU6JRWK=
NEC8 NUjLTGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jYOmlEPTB;MD63NlEyOyEQvF2= M1\NWHNCVkeHUh?=
SW756 NVTrR3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvMTWM2OD1yLkm5PFQ3KM7:TR?= MmftV2FPT0WU
A2780 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W3WmlEPTB;MT6wNVE1PiEQvF2= NHXlfmFUSU6JRWK=
NB14 NE\EUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vuTWlEPTB;MT6wNVgxOSEQvF2= NEXyc3pUSU6JRWK=
H4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXZc2hKSzVyPUGuNFY1OjJizszN NEDXTJFUSU6JRWK=
SK-OV-3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH4TWM2OD1zLkC2OlM{KM7:TR?= M1rSbXNCVkeHUh?=
AN3-CA M3PY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwMEizPFkh|ryP M{jNOnNCVkeHUh?=
A427 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHsWHRKUUN3ME2xMlExOzhzIN88US=> NELuenpUSU6JRWK=
ES7 NEjQeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH5Znh5UUN3ME2xMlEyOzN2IN88US=> NVziSm85W0GQR1XS
AGS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XJVmlEPTB;MT6xNVM6PSEQvF2= MlKyV2FPT0WU
G-402 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMUS2PVQh|ryP NID0dJlUSU6JRWK=
ES5 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe4[4Z[UUN3ME2xMlE4OjR6IN88US=> MXLTRW5ITVJ?
DEL M{LtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV74cnlnUUN3ME2xMlI2PDV5IN88US=> NVT5VZQ6W0GQR1XS
NB10 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPX[5hKSzVyPUGuN|I2PTdizszN M4XpS3NCVkeHUh?=
NCI-H1581 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzMRXFKSzVyPUGuN|kxPDJizszN Mlq4V2FPT0WU
D-566MG NWLhT5ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnGXGlKSzVyPUGuOFA3QDNizszN NGOzS2dUSU6JRWK=
LXF-289 NI\ndYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfYfopKSzVyPUGuOFM6QTZizszN M4\NfHNCVkeHUh?=
BT-549 NVXwfXhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTrTWM2OD1zLkW2PVA6KM7:TR?= NV:0N4F2W0GQR1XS
NKM-1 M3ezUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHkdnVKSzVyPUGuOlA2PTZizszN MYLTRW5ITVJ?
SW780 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rHXGlEPTB;MT62OVE2QCEQvF2= MkjUV2FPT0WU
NCI-H292 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXvVWJvUUN3ME2xMlY3Ozh|IN88US=> NF\mdXpUSU6JRWK=
HMV-II M1THNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr2cnJGUUN3ME2xMlcxPDh6IN88US=> NY[4bHdWW0GQR1XS
ALL-PO M17nOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD1zLkiwNFE2KM7:TR?= M2fF[3NCVkeHUh?=
UACC-257 NEfKVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTFwOEKxOlMh|ryP NID4OJZUSU6JRWK=
PA-1 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwOEK3NlUh|ryP NXHpZnNRW0GQR1XS
HD-MY-Z MmPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DW[GlEPTB;MT64OlI5OSEQvF2= M1XpeHNCVkeHUh?=
HSC-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;i[mlEPTB;MT65N|g{QSEQvF2= M1jNRXNCVkeHUh?=
GCT NH7vNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rPVWlEPTB;Mj6wNFkyPiEQvF2= MXPTRW5ITVJ?
RT-112 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnrboI1UUN3ME2yMlE{PDJ2IN88US=> M3\WeHNCVkeHUh?=
A172 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorOTWM2OD1{LkGzOlA3KM7:TR?= M3\RdXNCVkeHUh?=
HCE-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\sd2lEPTB;Mj6yNFU6QCEQvF2= NXzSNFZsW0GQR1XS
YH-13 NIfDT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXMTWM2OD1{LkKxOlcyKM7:TR?= NFrmc5FUSU6JRWK=
DK-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD1{LkKzPFM1KM7:TR?= NVzSVYJkW0GQR1XS
ACN NES2No9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjF[ZlIUUN3ME2yMlI{QDd3IN88US=> NGXlUWlUSU6JRWK=
VA-ES-BJ Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT1eVVMUUN3ME2yMlI1QTV5IN88US=> MoPtV2FPT0WU
L-363 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrFZm9uUUN3ME2yMlI5ODZzIN88US=> MVHTRW5ITVJ?
HuH-7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPYdVdKSzVyPUKuOFIyPjVizszN NIWxSYRUSU6JRWK=
A4-Fuk NV\sZol3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVeGlEPTB;Mj60O|E3QCEQvF2= MnLDV2FPT0WU
T-24 NXHlbmVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwNEiwN|ch|ryP NEHyN4pUSU6JRWK=
GOTO M{PCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\MTpRWUUN3ME2yMlU{ODF|IN88US=> NXjwfXUyW0GQR1XS
MV-4-11 NIrze5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lsd2lEPTB;Mj61PVE3QSEQvF2= MoPhV2FPT0WU
DMS-114 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNk[zOFUh|ryP NYHMUGlSW0GQR1XS
MHH-NB-11 M2HUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXtTWM2OD1{LkewNlk6KM7:TR?= NHnBcHZUSU6JRWK=
CHP-212 MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXrN5hKSzVyPUKuPFIxQTFizszN M1O5dXNCVkeHUh?=
DMS-273 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITHUZZKSzVyPUKuPVAzODdizszN M1iweXNCVkeHUh?=
SF295 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXXN|NzUUN3ME2zMlAzPTl5IN88US=> NHfQcmRUSU6JRWK=
NCI-H1563 NFm0[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XjfWlEPTB;Mz6xOVAxPSEQvF2= NVj0bZQ4W0GQR1XS
NCI-H446 NUDmWGZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjSTWM2OD1|LkKyPFA2KM7:TR?= M2XhcXNCVkeHUh?=
HCC1806 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrheWx2UUN3ME2zMlI4PjV5IN88US=> M2jNb3NCVkeHUh?=
SF126 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTyN|NIUUN3ME2zMlMxODF5IN88US=> NY\ibWYyW0GQR1XS
SW982 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNwM{O4O|Uh|ryP NYLnUJd3W0GQR1XS
ES8 NFzNd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnTc5RKSzVyPUOuN|Q6QTlizszN M3zCTHNCVkeHUh?=
SCC-4 M4Thcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwNUCzPVYh|ryP MVnTRW5ITVJ?
RPMI-8226 M3;rXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULtWJVOUUN3ME2zMlYzPjF4IN88US=> MoK2V2FPT0WU
EW-11 NX3le2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwNkOwNlIh|ryP NH;kNG1USU6JRWK=
COR-L105 NHv0fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0[WlEPTB;Mz62N|M{PCEQvF2= NF;ybI1USU6JRWK=
ES1 NEPidXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUD1eGNPUUN3ME2zMlg{ODl2IN88US=> NFHyRmJUSU6JRWK=
KMOE-2 NEXHd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfrNYtmUUN3ME2zMlkyQDB6IN88US=> M3\ERnNCVkeHUh?=
ABC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH6ToRKSzVyPUOuPVM6OTFizszN MWDTRW5ITVJ?
NCI-H526 NGP0XWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPLTWM2OD1|Lkm5NVI3KM7:TR?= MmLaV2FPT0WU
HCC1395 M{LrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTVTHE4UUN3ME2zMlk6PDh2IN88US=> M3jSS3NCVkeHUh?=
DU-145 NX;1Z5hNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvLNlB4UUN3ME20MlEzQDJ3IN88US=> MoCyV2FPT0WU
JEG-3 MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPsTWM2OD12LkG1PVE3KM7:TR?= M2TxUnNCVkeHUh?=
HCC1187 NGfCPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;UT5VKSzVyPUSuNlE2QTdizszN MlzDV2FPT0WU
LC-2-ad NGTHPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLwS4hwUUN3ME20MlIzOTd5IN88US=> M4PPR3NCVkeHUh?=
ONS-76 M3zJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGOz[W9KSzVyPUSuNlQyQTJizszN NHmxNJlUSU6JRWK=
CAL-27 NWXUSHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnjXWFIUUN3ME20MlI1OzR2IN88US=> MXHTRW5ITVJ?
8-MG-BA NWXjN3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfJWJpKUUN3ME20MlI3PjV6IN88US=> MlTEV2FPT0WU
HGC-27 NFXvfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPXTWM2OD12LkK5OlYh|ryP MnHPV2FPT0WU
Hs-578-T M1\hUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TWZWlEPTB;ND6zNVQ3QCEQvF2= MmLxV2FPT0WU
EW-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwNUOwNVQh|ryP MX;TRW5ITVJ?
SW1573 M1rUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfjTWM2OD12LkW1NVY{KM7:TR?= MkPDV2FPT0WU
SNU-423 NYHRSYVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfSc41KSzVyPUSuOlA4QSEQvF2= NV\weYUzW0GQR1XS
HOS M1X5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXeweIx7UUN3ME20MlY6PzdizszN M1HMSHNCVkeHUh?=
LB1047-RCC M1HqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7iWZJ[UUN3ME20MlgyPDF6IN88US=> MnO3V2FPT0WU
ChaGo-K-1 M{\JO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfHTWM2OD12Lki5NFQ5KM7:TR?= MWTTRW5ITVJ?
A3-KAW NYLnXHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTGPHVKSzVyPUSuPVc{PTJizszN MX\TRW5ITVJ?
CAS-1 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LheWlEPTB;ND65PVkxQCEQvF2= M{XMVHNCVkeHUh?=
NBsusSR NIPmVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDPb4lZUUN3ME21MlA{PTF2IN88US=> MmDyV2FPT0WU
KM12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPFTWM2OD13LkK5PFI4KM7:TR?= NXTYUmpMW0GQR1XS
NCI-H1155 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTuTWM2OD13LkO4NVg2KM7:TR?= MkjSV2FPT0WU
EFM-19 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTVwNEG3N|ch|ryP NVzmfJlpW0GQR1XS
D-392MG MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nhZmlEPTB;NT61O|g1QSEQvF2= MV\TRW5ITVJ?
JVM-3 NUmxdnNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD13LkeyN|I2KM7:TR?= NF63bnZUSU6JRWK=
EW-16 MkXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrV[4dkUUN3ME21Mlc2PTh|IN88US=> NYHTO|kzW0GQR1XS
KARPAS-45 NGX0fWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIftVHdKSzVyPUWuPFQ{OjVizszN MYXTRW5ITVJ?
NCI-H28 NEfSenpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwOEe5NVgh|ryP NHz5XJZUSU6JRWK=
COLO-829 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\JTWM2OD13LkmxOVA1KM7:TR?= MmG0V2FPT0WU
KM-H2 NFmxVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjYNFljUUN3ME21MlkzOzl3IN88US=> NVe5WJNNW0GQR1XS
NCI-H82 NEK0bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrhTWM2OD13LkmyO|cyKM7:TR?= MmHtV2FPT0WU
OAW-42 NEjYN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTVwOUi4NlEh|ryP M1H4dXNCVkeHUh?=
A704 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjDcJVKSzVyPU[uNVA2PzRizszN MnzUV2FPT0WU
NCI-H1048 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrOdYtKSzVyPU[uNVA2QTlizszN NH76VVlUSU6JRWK=
LOXIMVI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX64cY1jUUN3ME22MlEyOjR6IN88US=> M1\vRXNCVkeHUh?=
MKN45 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHwUJlGUUN3ME22MlI3ODF4IN88US=> NVrTbFlqW0GQR1XS
D-502MG MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzBTWM2OD14LkK4PFU4KM7:TR?= NYrZZlVoW0GQR1XS
HUTU-80 NInYW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DtR2lEPTB;Nj60NVY5QCEQvF2= NVH2Z3VQW0GQR1XS
S-117 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTZwNUCyOlch|ryP Mn\YV2FPT0WU
HCC1569 M{fSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\5NWlEPTB;Nj61N|c{PyEQvF2= NV3FeXlNW0GQR1XS
J-RT3-T3-5 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTZwNUS1O|Ih|ryP MVLTRW5ITVJ?
OC-314 M{naSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfseXBKSzVyPU[uPVEyPTlizszN MXLTRW5ITVJ?
SNU-449 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwMEGwO|Ih|ryP NEe5fZRUSU6JRWK=
NCI-H720 NGPsZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr3TFREUUN3ME23MlE6OzR3IN88US=> M3TLZnNCVkeHUh?=
KP-N-YS Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz0[3pKSzVyPUeuNlA4OiEQvF2= NEnyT4xUSU6JRWK=
IGROV-1 NELCc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLTTWM2OD15LkOyN|g3KM7:TR?= NEKzR4NUSU6JRWK=
SK-PN-DW M{K0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDuWpQxUUN3ME23MlQ5OTVizszN NGHVPJBUSU6JRWK=
HCC1419 M3POWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwNUOg{txO MkLkV2FPT0WU
HAL-01 NITJemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;4TWM2OD15Lk[wOlQ1KM7:TR?= MlzTV2FPT0WU
HCC2998 NEHVPW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTdwNkC3OFMh|ryP Mo[4V2FPT0WU
SK-N-FI MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTdwNkOwN|Mh|ryP MojzV2FPT0WU
GI-ME-N NF;TUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTdwNkS5N|Qh|ryP NE[5UI5USU6JRWK=
SW1088 NFXPe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO1flJKSzVyPUeuOlU5OjZizszN MmLDV2FPT0WU
IA-LM M1vOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jLT2lEPTB;Nz62PFYyOyEQvF2= M2HrXnNCVkeHUh?=
SK-NEP-1 M{TJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHqTWM2OD15Lk[5OlEh|ryP M3TmN3NCVkeHUh?=
MDA-MB-415 NXPqTGNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf2R3dKSzVyPUeuPFkyQDZizszN NV30[JZ5W0GQR1XS
COLO-800 NUToc5BqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:5b49KSzVyPUeuPVQ1QTJizszN MnnGV2FPT0WU
NCI-H2228 NGL2d4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhO5ZKSzVyPUiuNVU4QDNizszN Mn[xV2FPT0WU
D-423MG MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvKe5pKSzVyPUiuNlE4OiEQvF2= M1HOWXNCVkeHUh?=
TE-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TxfmlEPTB;OD60OFMyPiEQvF2= MVrTRW5ITVJ?
NOS-1 NETTfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvVXYxKSzVyPUiuOVE2OzRizszN MY\TRW5ITVJ?
8505C MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHONXg6UUN3ME24MlY1QDJ2IN88US=> MmDNV2FPT0WU
HEC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSTWM2OD16Lke4OFM6KM7:TR?= NXPLR4EyW0GQR1XS
TE-11 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;WR2lEPTB;OD65PVU2OSEQvF2= NV6yW4ZxW0GQR1XS
CTB-1 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTlwMEG0N|Mh|ryP NFrCbnlUSU6JRWK=
TGBC11TKB NIi2bG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTlwMEKyOFEh|ryP MoOxV2FPT0WU
NB17 NFfIWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlwMUi4O{DPxE1? NG\pTVJUSU6JRWK=
Becker MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq4TWM2OD17LkSxPVQ1KM7:TR?= MU\TRW5ITVJ?
SN12C NVzWeXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO3TWM2OD17LkS1NlM1KM7:TR?= NF\4NWtUSU6JRWK=
COLO-320-HSR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6xUIFOUUN3ME25MlYxOjN5IN88US=> M2[yN3NCVkeHUh?=
D-283MED M2PQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULB[IVOUUN3ME25MlY{ODd{IN88US=> NWfQZmFHW0GQR1XS
D-263MG MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[wTWlEPTB;OT64N|M5PCEQvF2= MoOwV2FPT0WU
MEL-JUSO M2T5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XaOWlEPTB;OT65NFEzPyEQvF2= NXTLZ3RrW0GQR1XS
T98G MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnH[|U1UUN3ME25MlkxOjB|IN88US=> MXXTRW5ITVJ?
HLE M3rXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\SUIdKSzVyPUmuPVA6ODlizszN MYPTRW5ITVJ?
Ca9-22 NGjPPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nFNGlEPTB;MUCuNFY3PSEQvF2= MWfTRW5ITVJ?
OS-RC-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTVTWM2OD1zMD6xNFQ2KM7:TR?= M3izZ3NCVkeHUh?=
T47D NYrPOJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFyLkG1OUDPxE1? NWDFUnBRW0GQR1XS
GI-1 NW\a[2prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFyLkO1N|Mh|ryP NIfPPXBUSU6JRWK=
NUGC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjIWJlKSzVyPUGwMlQ1ODJizszN M3rpenNCVkeHUh?=
MDA-MB-361 M3zz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[1S|BOUUN3ME2xNE41PDN{IN88US=> NHPPXVlUSU6JRWK=
SCC-15 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5OpdKSzVyPUGwMlQ4OThizszN MYDTRW5ITVJ?
KS-1 NHXiNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\zcYdKSzVyPUGwMlY{ODFizszN M2DSTXNCVkeHUh?=
CAL-12T M{jsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjPWYlKSzVyPUGwMlY{PjFizszN MnzjV2FPT0WU
OVCAR-4 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPub3FXUUN3ME2xNE44ODZ6IN88US=> M1;SXnNCVkeHUh?=
HuP-T4 M1rib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFzLkCzNlgh|ryP MV;TRW5ITVJ?
NCI-H358 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\2fJFlUUN3ME2xNU4zPjV5IN88US=> NUPjbVF5W0GQR1XS
HO-1-N-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4Z2lEPTB;MUGuN|M6QCEQvF2= MoPGV2FPT0WU
NH-12 NVe1SmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjNTWM2OD1zMT61N|c5KM7:TR?= MXTTRW5ITVJ?
MOLT-4 MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTFzLkW5PFUh|ryP MorIV2FPT0WU
K-562 NYHXVWhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmV4R7UUN3ME2xNU44OjR6IN88US=> NUXFbIs3W0GQR1XS
ES6 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfPU4tKSzVyPUGxMlg2QDFizszN NIDSSHdUSU6JRWK=
RO82-W-1 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;GTmNYUUN3ME2xNU46ODZ2IN88US=> NXu3XI4xW0GQR1XS
Ramos-2G6-4C10 M4LPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6zbWVKSzVyPUGxMlk{OiEQvF2= M3vXSXNCVkeHUh?=
23132-87 Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLvR5FKSzVyPUGyMlA5OjFizszN MmXUV2FPT0WU
A549 NXz1NmhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[wXYJCUUN3ME2xNk4{Ojh3IN88US=> NWTLV3hPW0GQR1XS
NCI-H23 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF{LkWwNlYh|ryP Mn\XV2FPT0WU
H9 NHXSWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHkdHhkUUN3ME2xNk42PTd5IN88US=> M4\Vc3NCVkeHUh?=
LB771-HNC NF3LUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF{Lke2OUDPxE1? MkXCV2FPT0WU
QIMR-WIL MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWexTXp5UUN3ME2xNk45OjV6IN88US=> M1vUOHNCVkeHUh?=
HSC-3 M2H5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF{LkmyO|Yh|ryP MXLTRW5ITVJ?
PFSK-1 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfaTWM2OD1zMj65OVA4KM7:TR?= NIDJS3RUSU6JRWK=
ETK-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Lj[WlEPTB;MUOuNFc4QSEQvF2= MmTMV2FPT0WU
SW1710 NG\F[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzi[3hlUUN3ME2xN{4{PjRzIN88US=> M2HLfHNCVkeHUh?=
COLO-684 NEDuUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3aZ5FKSzVyPUGzMlQ2PDFizszN MkD0V2FPT0WU
RPMI-7951 M3XQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XPcWlEPTB;MUOuOVE{PiEQvF2= NF;1XJRUSU6JRWK=
A101D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VV2E5UUN3ME2xN{42OzR7IN88US=> M3PQWHNCVkeHUh?=
KE-37 NUDrRohoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LSbGlEPTB;MUOuOVg5PyEQvF2= NUXRd4R3W0GQR1XS
SiHa M{fMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrqRnVKSzVyPUGzMlg{PDZizszN MY\TRW5ITVJ?
NCI-H226 Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF|Lki4NFgh|ryP NF;ZTo9USU6JRWK=
DB NV;tUGRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3TTWM2OD1zMz65PVI5KM7:TR?= M1\JdXNCVkeHUh?=
HT-1197 MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHDOVFwUUN3ME2xOE4xQDB7IN88US=> Mon1V2FPT0WU
SBC-5 M4[5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nl[GlEPTB;MUSuNVM3OiEQvF2= M2DJZnNCVkeHUh?=
VMRC-RCZ MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjZemRKSzVyPUG0MlU4PzRizszN MXfTRW5ITVJ?
697 NWn4e4dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHYTWM2OD1zND62Nlch|ryP MkHBV2FPT0WU
OMC-1 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF2Lke4PFgh|ryP M2fUdnNCVkeHUh?=
SKG-IIIa NGL3[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1zND64NFAyKM7:TR?= M1G5dnNCVkeHUh?=
DOK NX3adGZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF2Lkm5N|Mh|ryP MlfQV2FPT0WU
NCI-H2029 NX;pZVJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV33WWVNUUN3ME2xOU4{PjB{IN88US=> MXPTRW5ITVJ?
NCI-H2009 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH1TWM2OD1zNT61NFk2KM7:TR?= NWWzR2lMW0GQR1XS
LK-2 M3;VVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\XfFNXUUN3ME2xOU43PDR7IN88US=> M1Ox[nNCVkeHUh?=
NCI-H661 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF3LkmwO|Uh|ryP NHvTbpVUSU6JRWK=
GT3TKB MlfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy2RnBlUUN3ME2xOk4xPjd4IN88US=> MV;TRW5ITVJ?
GP5d NFzlO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTF4LkO0NkDPxE1? NIfuSnpUSU6JRWK=
SK-MEL-2 M2i3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTF4LkS0PFUh|ryP NYnnTXBHW0GQR1XS
SK-UT-1 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxNphRUUN3ME2xOk42PjVizszN NFfZOGpUSU6JRWK=
NB7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPkTWM2OD1zNj62PVcyKM7:TR?= MlG1V2FPT0WU
NCI-H460 NHTjSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ZO|kyUUN3ME2xOk44OzJ4IN88US=> NVjjUVZJW0GQR1XS
8305C M{Haemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF4Lke4O|ch|ryP NYLoU4tZW0GQR1XS
CaR-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTF4LkixNVEh|ryP NHvBeFFUSU6JRWK=
D-247MG NHLSZ5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\PZWlEPTB;MU[uPFYzPSEQvF2= M3vMb3NCVkeHUh?=
LoVo MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF4Lkm0PFgh|ryP NXf1Ros2W0GQR1XS
NCI-H2405 MkPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonLTWM2OD1zNz6xPVA5KM7:TR?= M2HRdHNCVkeHUh?=
AU565 NILMfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHkbpRKSzVyPUG3MlIzPSEQvF2= MX7TRW5ITVJ?
OCI-AML2 NX7FSVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoP3TWM2OD1zNz61N|E4KM7:TR?= NVTQTWdqW0GQR1XS
22RV1 M4HsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf0TWM2OD1zNz61PFg1KM7:TR?= M{O2cHNCVkeHUh?=
HT-144 MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\wfHpHUUN3ME2xO{43PTl6IN88US=> NUHsfWhtW0GQR1XS
HuO9 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnWSVdKSzVyPUG3MlcxOzFizszN MYDTRW5ITVJ?
Daoy MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n2ZWlEPTB;MUeuO|E5PCEQvF2= M3;pNXNCVkeHUh?=
SJRH30 NEixOIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTF5Lki0PFkh|ryP NYD6V3k2W0GQR1XS
CHL-1 Ml:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILXenVKSzVyPUG3MlkzPDlizszN M{S2U3NCVkeHUh?=
J82 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;mTWM2OD1zNz65OlM2KM7:TR?= M1;ESnNCVkeHUh?=
COR-L23 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\0XVliUUN3ME2xPE4xODFzIN88US=> NEXBUIFUSU6JRWK=
SNU-C2B NIft[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle3TWM2OD1zOD6yNlc3KM7:TR?= NEHufmlUSU6JRWK=
NCI-H1770 M3PnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjOe4RYUUN3ME2xPE41PjF3IN88US=> NWjKO2V6W0GQR1XS
MHH-PREB-1 NWPFeoRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXqd4Q4UUN3ME2xPE42Pjl5IN88US=> MWjTRW5ITVJ?
ES3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzBenJKSzVyPUG4MlU5QDNizszN M3W3d3NCVkeHUh?=
MDA-MB-231 NEW0N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFKwWJdKSzVyPUG4MlY2ODJizszN Mnu0V2FPT0WU
MN-60 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPITWM2OD1zOT6wOVkzKM7:TR?= NVTvO3AzW0GQR1XS
EPLC-272H M{L3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF7LkO3NFgh|ryP NXzKOJdjW0GQR1XS
SW948 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13adWlEPTB;MUmuN|k{PCEQvF2= NI\PclFUSU6JRWK=
MOLT-13 NU\mfZJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK5TWM2OD1zOT60OVQ3KM7:TR?= MoPqV2FPT0WU
HL-60 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTJyLkKxOFEh|ryP NFT6[XhUSU6JRWK=
CP50-MEL-B M2POb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfyTWM2OD1{MD60O|Q5KM7:TR?= MXvTRW5ITVJ?
NTERA-S-cl-D1 NFflZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTETWM2OD1{MD60PVc5KM7:TR?= NXiwemVRW0GQR1XS
KINGS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnhTWM2OD1{MD63PVY4KM7:TR?= NVe3enRIW0GQR1XS
DOHH-2 NFzsZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsTGZKSzVyPUKwMlkxPiEQvF2= MV;TRW5ITVJ?
BB65-RCC M3\VVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfDOFR5UUN3ME2yNE46Ojh3IN88US=> MlnOV2FPT0WU
NB12 M1;YbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFflfmNKSzVyPUKxMlA{QTRizszN M4HMRXNCVkeHUh?=
KY821 Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\5PZhKSzVyPUKxMlU5OiEQvF2= NUXDbG1rW0GQR1XS
PSN1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJzLk[0OVMh|ryP MXLTRW5ITVJ?
EGI-1 NELG[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJzLke0OVQh|ryP NFTsZZhUSU6JRWK=
CTV-1 NF21OIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnrbJFlUUN3ME2yNk4{ODNzIN88US=> MnPTV2FPT0WU
TI-73 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rHfGlEPTB;MkKuN|Q6QCEQvF2= Mlu4V2FPT0WU
LCLC-103H NUfBWZlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn0VGU3UUN3ME2yNk41PzV{IN88US=> MWfTRW5ITVJ?
D-542MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7GTWM2OD1{Mj61OVU5KM7:TR?= NG\uWIFUSU6JRWK=
ATN-1 NV[yWJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJ{Lk[0N|kh|ryP M1frTXNCVkeHUh?=
SK-MEL-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO4UlU3UUN3ME2yNk45OzZ6IN88US=> MmHMV2FPT0WU
HDLM-2 NIK1TlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJ|LkG0O|gh|ryP NH3N[FJUSU6JRWK=
UM-UC-3 NGfYbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTVTWM2OD1{Mz6xPVQ1KM7:TR?= MWHTRW5ITVJ?
NCI-H1573 M4HPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoflTWM2OD1{Mz60OlgyKM7:TR?= NF3JSpBUSU6JRWK=
NCI-H520 M3qyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nKd2lEPTB;MkOuOFk1QCEQvF2= NGrQe|NUSU6JRWK=
ESS-1 MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHzTWM2OD1{Mz64NFU6KM7:TR?= MYDTRW5ITVJ?
COR-L88 M3;1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ|Lkm0O|Uh|ryP NEfz[G1USU6JRWK=
TGBC24TKB NYi4e2V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjxclltUUN3ME2yOE4xOzF{IN88US=> NXnBcmtIW0GQR1XS
HCC1937 NXr0[FBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3sOohKSzVyPUK0MlEh|ryP NH[zc4lUSU6JRWK=
RS4-11 NVPGSm5UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:5clV7UUN3ME2yOE4yPDJizszN MkK2V2FPT0WU
HCC38 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn3colKSzVyPUK0MlI{QTRizszN NVrpNnU1W0GQR1XS
RPMI-2650 NFm4VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1{ND62NVYzKM7:TR?= MlLnV2FPT0WU
P12-ICHIKAWA NWnIcWhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rEV2lEPTB;MkSuOlI2QCEQvF2= MVvTRW5ITVJ?
YAPC M174U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjP[VdRUUN3ME2yOE45OjF2IN88US=> NGezeJlUSU6JRWK=
NB13 NE\UVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\v[|VxUUN3ME2yOU4zPjFzIN88US=> M{DZSnNCVkeHUh?=
SK-N-AS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJ3Lki1PFQh|ryP NXTqfW1pW0GQR1XS
SK-N-DZ M2XiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3iXmtFUUN3ME2yOk4xPDlizszN M4rmXHNCVkeHUh?=
LS-411N MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC0UI1VUUN3ME2yOk4zODN6IN88US=> NG\XRYZUSU6JRWK=
NCI-H810 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD0NZp{UUN3ME2yOk4{OTF{IN88US=> M2PN[HNCVkeHUh?=
NCI-SNU-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0dmlEPTB;Mk[uOVQ2PCEQvF2= NIPwPGhUSU6JRWK=
HH M3\5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHsW|NNUUN3ME2yOk42PTJ7IN88US=> NWf1e4NtW0GQR1XS
U-2-OS MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDzVW1KSzVyPUK2Mlc{QDJizszN M1i3Z3NCVkeHUh?=
SF539 NX\vPG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHER5hKSzVyPUK2MlgxOThizszN MVjTRW5ITVJ?
NCI-H2052 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ5LkC4OkDPxE1? NYfqdVY5W0GQR1XS
A673 NGLPd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ5LkKxNFIh|ryP M2\RcHNCVkeHUh?=
WM-115 NUDZeppIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrhZW1lUUN3ME2yO{44PzZ5IN88US=> M2jqOHNCVkeHUh?=
SW48 NEHx[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\XUVRKSzVyPUK3MlgxODVizszN MlTkV2FPT0WU
NOMO-1 NVqxTXR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDaTWM2OD1{Nz64OVMzKM7:TR?= MkKwV2FPT0WU
PC-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTJ5Lki5OFEh|ryP NFy3bVVUSU6JRWK=
UMC-11 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXJTYRKSzVyPUK3Mlk{PDNizszN Ml:1V2FPT0WU
U-118-MG NGrsZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vLVWlEPTB;MkiuNFEzOyEQvF2= M3PudHNCVkeHUh?=
NCI-H2452 MoHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPacGh4UUN3ME2yPE4xQDJ{IN88US=> MYfTRW5ITVJ?
CAMA-1 MnjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTKR2tjUUN3ME2yPE45PTZ2IN88US=> MmDQV2FPT0WU
MC-IXC M2fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HJZ2lEPTB;MkmuNlM3PiEQvF2= MXPTRW5ITVJ?
ES4 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXrVoZKSzVyPUK5MlMyPzJizszN MVrTRW5ITVJ?
BHT-101 NF\IeYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv0TWM2OD1{OT6zNlEh|ryP NYr6OW9LW0GQR1XS
KP-4 M3;pSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV21enp[UUN3ME2yPU42OTZizszN M1[zc3NCVkeHUh?=
CAL-54 MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PHb2lEPTB;MkmuOVQ1PSEQvF2= M4TsRnNCVkeHUh?=
5637 NFnK[lVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ7Lk[0NlEh|ryP MnnEV2FPT0WU
MOLT-16 NEDZR2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HWUmlEPTB;MkmuO|I3QSEQvF2= MofVV2FPT0WU
Ca-Ski NV;4dY0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2ridGlEPTB;MkmuPVQ3KM7:TR?= MYXTRW5ITVJ?
AsPC-1 M1XHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTNyLkCyNVIh|ryP MnXVV2FPT0WU
MSTO-211H NHHJcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC5[5d4UUN3ME2zNE4yPSEQvF2= NEfmNpdUSU6JRWK=
L-428 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLRfY9WUUN3ME2zNE41ODVizszN Mlz0V2FPT0WU
SW1463 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe2TWM2OD1|MD61N|g{KM7:TR?= NUCwd3BYW0GQR1XS
NCI-H1648 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV35NVlJUUN3ME2zNE42PTd2IN88US=> MWrTRW5ITVJ?
CAKI-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzkN3lKSzVyPUOwMlc4ODJizszN NXv5[5pyW0GQR1XS
YKG-1 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTNzLkCyOlMh|ryP NUnSSlg6W0GQR1XS
A2058 MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HYb2lEPTB;M{GuNVE3PCEQvF2= NUDoSZhbW0GQR1XS
A375 NWP4eIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNzLkG2PVYh|ryP NYHEV29MW0GQR1XS
SNB75 NV\iVZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNzLkK0N|Uh|ryP NGPtSnFUSU6JRWK=
SK-HEP-1 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\1XGlEPTB;M{GuOFI4OSEQvF2= NX[zT2l1W0GQR1XS
ME-180 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTpTWM2OD1|MT62OVQzKM7:TR?= MVTTRW5ITVJ?
NCI-H209 NYe0cnNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTNzLkiyOFch|ryP NEfRSnRUSU6JRWK=
HC-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULi[nFwUUN3ME2zNk4yPDR4IN88US=> MojnV2FPT0WU
LB373-MEL-D MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\kbWlEPTB;M{KuNVk4OSEQvF2= NYPnNVNlW0GQR1XS
SNU-387 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UTWM2OD1|Mj6zNVkyKM7:TR?= MVXTRW5ITVJ?
C32 NXjlRpdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;zZo5KSzVyPUOyMlM{PTNizszN NUf4TG5rW0GQR1XS
EW-13 M3e4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqyeVJKSzVyPUOyMlk1ODhizszN MUjTRW5ITVJ?
BFTC-905 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnFTWM2OD1|Mz61NVM3KM7:TR?= M{HGTXNCVkeHUh?=
NCI-H1299 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDFTWM2OD1|Mz61OlIyKM7:TR?= NHrvNGRUSU6JRWK=
LU-135 NVH6W3gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITydIxKSzVyPUOzMlgxOSEQvF2= MU\TRW5ITVJ?
NCI-H2122 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[1U2lEPTB;M{OuPVk3PiEQvF2= NUP3V4h3W0GQR1XS
SK-LMS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNXnpKUUN3ME2zOE41OTB5IN88US=> MluyV2FPT0WU
LNCaP-Clone-FGC MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXDTWM2OD1|ND64OVE2KM7:TR?= NFS1coNUSU6JRWK=
NCI-H1092 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrndnJiUUN3ME2zOU4zPzR5IN88US=> MVTTRW5ITVJ?
MS-1 NF7ScIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTScphKSzVyPUO1MlMxOzhizszN Mo\sV2FPT0WU
KYSE-510 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTN3LkWwOFIh|ryP NGXNcGpUSU6JRWK=
NCI-H1793 NUDFN4lkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTh[pZKSzVyPUO1MlY2PDVizszN MmXZV2FPT0WU
MIA-PaCa-2 NX74PGd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN4LkC0PVYh|ryP NVnGOphwW0GQR1XS
EW-22 MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7oWJdmUUN3ME2zOk41ODd{IN88US=> MnLuV2FPT0WU
IGR-1 M1XGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnDTWM2OD1|Nj64NVg1KM7:TR?= MWXTRW5ITVJ?
HT-1080 NIL3N4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny4TWM2OD1|Nz6xNlUh|ryP NYGxc217W0GQR1XS
M14 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN5LkG2OFIh|ryP Mn[3V2FPT0WU
786-0 NHqyPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ThcWlEPTB;M{euNlc6PCEQvF2= NGH6WXpUSU6JRWK=
MZ2-MEL NXHDeIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTN5LkS1NFEh|ryP NFfIOXFUSU6JRWK=
NCI-H510A MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16yfGlEPTB;M{euPVQyOiEQvF2= MlHrV2FPT0WU
LAN-6 NFTKVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37tN2lEPTB;M{euPVU5OiEQvF2= NUjEUFJQW0GQR1XS
SW620 NUjiNXZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPXNHA4UUN3ME2zPE41QTd2IN88US=> MVvTRW5ITVJ?
LB2241-RCC MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHMVYR[UUN3ME2zPU45OjB3IN88US=> Mn\5V2FPT0WU
Detroit562 M2rYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\kTWM2OD12MD6xNlY5KM7:TR?= MULTRW5ITVJ?
HN M3HNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;JTWM2OD12MD6xO|gzKM7:TR?= Mo\HV2FPT0WU
HCT-15 MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lkc2lEPTB;NECuOVkxPyEQvF2= M3PZfnNCVkeHUh?=
C2BBe1 NXHPb28{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz1c|V3UUN3ME20NE46OTV5IN88US=> M3HEUnNCVkeHUh?=
A498 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljZTWM2OD12MT6zNFE2KM7:TR?= MX\TRW5ITVJ?
SK-MEL-24 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[2TWM2OD12MT60O|I2KM7:TR?= MUHTRW5ITVJ?
OVCAR-5 NYfBNXJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;lNXpKSzVyPUSxMlc4PjdizszN MXXTRW5ITVJ?
NCI-H1792 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7NZ3hKSzVyPUSxMlk5OjFizszN NH3ObHNUSU6JRWK=
KOSC-2 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTR{LkK2PVkh|ryP NGj4S|FUSU6JRWK=
Mo-T NUXGW5lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPEbXdTUUN3ME20Nk45QTV6IN88US=> MYrTRW5ITVJ?
CFPAC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR|LkS5OFQh|ryP MnXSV2FPT0WU
CAL-51 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;UWmlEPTB;NEOuOVYxPSEQvF2= NIHVPWpUSU6JRWK=
RH-18 NIHabppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HwVWlEPTB;NEOuPFA2KM7:TR?= NVTOSo85W0GQR1XS
EC-GI-10 NFvTfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\OTIRKSzVyPUSzMlg{PDdizszN MXPTRW5ITVJ?
HSC-2 MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPxOmlKSzVyPUS0MlAxQSEQvF2= NEfoclJUSU6JRWK=
ML-2 M1\nSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTR3LkK2NlEh|ryP MmPVV2FPT0WU
KNS-81-FD MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn32TWM2OD12NT63N|Y2KM7:TR?= NIXab4VUSU6JRWK=
NB6 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PRZ2lEPTB;NE[uNVEyKM7:TR?= MV7TRW5ITVJ?
MCF7 M2DHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnnVmtzUUN3ME20Ok42PTN|IN88US=> NGOzVXNUSU6JRWK=
P30-OHK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD12Nj64NVE4KM7:TR?= MoXWV2FPT0WU
BPH-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTR4Lkm4NFUh|ryP M2e4cXNCVkeHUh?=
U251 NGjUS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInNN2lKSzVyPUS2Mlk6PCEQvF2= NXjkS49iW0GQR1XS
MKN1 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnGOFBKSzVyPUS3MlUyOzdizszN NXH6eHg2W0GQR1XS
A431 NWLM[WdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnEUo95UUN3ME20O{45OzN6IN88US=> NVH0VXJQW0GQR1XS
C8166 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR7LkKwN|kh|ryP M1vk[XNCVkeHUh?=
HEL MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HZVWlEPTB;NEmuOFA3PCEQvF2= NHyxb5VUSU6JRWK=
RMG-I NUHYPGdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR7LkS0OFQh|ryP NEezPJBUSU6JRWK=
CAL-72 M{DlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR7Lk[wO|Uh|ryP NUj5[oVsW0GQR1XS
SW962 M{PVZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwb5JKSzVyPUS5Mlk{OzJizszN MWPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
0.5% CMC
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    We would like to store at -80℃ after it dissolved in CMC. Do you have any infomation about the suggested concentration in CMC?

  • Answer:

    Axitinib in 0.5% CMC at up to 30mg/ml is a suspension for oral gavage administration only. We don't suggest customer to freeze down the solution but to make fresh if possible. Customer can store it for 1-2 weeks at 4 degree for continuous use.

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID